SMC initial assessment of evidence for voretigene neparvovec (Luxturna) for treatment of vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations

The SMC has advised that the Scottish Government Medicines Policy Branch will notify Health Boards when this medicine is available for prescribing within the ultra-orphan pathway. In the meantime, requests for treatment should be considered through local non-formulary processes.


Scottish Medicines Consortium